Moderna (MRNA) reported a Q4 loss Friday of $2.91 per diluted share, swinging from a profit of $0.55 a year earlier.
Analysts polled by FactSet expected a loss of $2.83.
Revenue for the quarter ended Dec. 31 was $966 million compared with $2.81 billion a year earlier.
Analysts surveyed by FactSet expected $942.8 million.
The company reiterated its 2025 revenue guidance of $1.5 billion to $2.5 billion. Analysts polled by FactSet expect $2.36 billion.
Moderna shares fell more than 5% in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。